Journal Article

Phase II trial of Remitogen™ (humanized 1D10) monoclonal antibody targeting class II in patients with relapsed low-grade or follicular lymphoma

Clinical Lymphoma (2001) 2(3) 188-190
DOI: 10.3816/CLM.2001.n.026
26Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.
Get full text

Cite

CITATION STYLE

APA

Brown, K. S., Levitt, D. J., Shannon, M., & Link, B. K. (2001). Phase II trial of RemitogenTM (humanized 1D10) monoclonal antibody targeting class II in patients with relapsed low-grade or follicular lymphoma. Clinical Lymphoma, 2(3), 188–190. https://doi.org/10.3816/CLM.2001.n.026

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free